Comparative Pharmacology
Head-to-head clinical analysis: DEMEROL versus DOLOPHINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMEROL versus DOLOPHINE HYDROCHLORIDE.
DEMEROL vs DOLOPHINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia, sedation, and euphoria. It also has additional weak actions at kappa and delta receptors.
Methadone is a mu-opioid receptor agonist with additional NMDA receptor antagonism and serotonin/norepinephrine reuptake inhibition. It also binds to delta and kappa opioid receptors, producing analgesic and antitussive effects.
50-150 mg IM, IV, or SC every 3-4 hours as needed for pain; oral 50-150 mg every 3-4 hours.
Initial: 2.5-10 mg orally every 8-12 hours, titrating to effect. Maintenance: 5-20 mg orally every 8-12 hours. For severe chronic pain, dosing interval may be extended to every 12-24 hours due to long half-life. Not recommended for acute pain or as PRN analgesia.
None Documented
None Documented
2.5-4 hours; prolonged in hepatic impairment (7-11 hours) and elderly.
Terminal elimination half-life: 15 to 60 hours (average 24-36 hours). Clinical context: Prolonged half-life due to extensive tissue binding and redistribution; accumulates with repeated dosing, requiring careful titration to avoid toxicity.
Renal (90% as metabolites and unchanged drug; ~5% unchanged) and biliary/fecal (minor).
Primarily renal elimination of unchanged drug (approximately 50-60%) and metabolites (including the inactive metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine). Fecal excretion accounts for about 10-20%. Biliary excretion contributes minimally (<5%) to overall elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic